Performance Evaluation of Three Antibody Binding Assays, a Neutralizing Antibody Assay, and an Interferon-Gamma Release Assay for SARS-CoV-2 According to Vaccine Type in Vaccinated Group
We evaluated the performance of SARS-CoV-2 assays in the vaccinated group using receptor-binding domain antibody assays (RBD Ab assay), neutralizing antibody assay (nAb assay), and interferon-gamma release assay (IGR assay). We also compared the performance of the SARS-CoV-2 assays based on vaccine...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-12-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/13/24/3688 |
| _version_ | 1797381410854535168 |
|---|---|
| author | Minjeong Nam Jae Hyun Cha Sang-Wook Kim Sun Bean Kim Ki-Byung Lee You-Seung Chung Seung Gyu Yun Myung-Hyun Nam Chang Kyu Lee Yunjung Cho |
| author_facet | Minjeong Nam Jae Hyun Cha Sang-Wook Kim Sun Bean Kim Ki-Byung Lee You-Seung Chung Seung Gyu Yun Myung-Hyun Nam Chang Kyu Lee Yunjung Cho |
| author_sort | Minjeong Nam |
| collection | DOAJ |
| description | We evaluated the performance of SARS-CoV-2 assays in the vaccinated group using receptor-binding domain antibody assays (RBD Ab assay), neutralizing antibody assay (nAb assay), and interferon-gamma release assay (IGR assay). We also compared the performance of the SARS-CoV-2 assays based on vaccine type in a large population. We collected 1851 samples from vaccinated individuals with vector, mix-and-match (MM), and mRNA vaccines. The performance of the RBD Ab assays was assessed by SARS-CoV-2 IgG II Quant (Abbott Laboratories, Sligo, Ireland), SARS-CoV-2 IgG (Beckman Coulter, CA, USA), and anti-SARS-CoV-2 S (Roche Diagnostics GmbH, Mannheim, Germany). The nAb assay was assessed by cPass SARS-CoV-2 neutralization antibody detection kits (GenScript, NJ, USA). The IGR assay was assessed by QuantiFERON (Qiagen, Venlo, The Netherlands). Median values of the RBD Ab assays and nAb assay sequentially increased after the first and second vaccinations. RBD Ab assays and nAb assay showed very strong correlations. The median values of the RBD Ab, nAb, and IGR were higher in the mRNA vaccine group than in the vector and MM vaccine groups. The agreement and correlation among the RBD Ab assays, nAb assay, and IGR assay were higher in the mRNA vaccine group than in the vector and MM vaccine groups. We compared the performance of the RBD Ab assay, nAb assay, and IGR assay based on the vaccine types using the RBD Ab, nAb, and IGR assays. This study provides a better understanding of the assessment of humoral and cellular immune responses after vaccination. |
| first_indexed | 2024-03-08T20:52:08Z |
| format | Article |
| id | doaj.art-c91424657d02464cafbd6e0ce6fd7485 |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-08T20:52:08Z |
| publishDate | 2023-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-c91424657d02464cafbd6e0ce6fd74852023-12-22T14:03:21ZengMDPI AGDiagnostics2075-44182023-12-011324368810.3390/diagnostics13243688Performance Evaluation of Three Antibody Binding Assays, a Neutralizing Antibody Assay, and an Interferon-Gamma Release Assay for SARS-CoV-2 According to Vaccine Type in Vaccinated GroupMinjeong Nam0Jae Hyun Cha1Sang-Wook Kim2Sun Bean Kim3Ki-Byung Lee4You-Seung Chung5Seung Gyu Yun6Myung-Hyun Nam7Chang Kyu Lee8Yunjung Cho9Department of Laboratory Medicine, Korea University College of Medicine, Seoul 02841, Republic of KoreaDepartment of Laboratory Medicine, Korea University Anam Hospital, Seoul 02841, Republic of KoreaDepartment of Laboratory Medicine, Korea University Anam Hospital, Seoul 02841, Republic of KoreaDivision of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Korea University Anam Hospital, Seoul 02841, Republic of KoreaDivision of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Korea University Anam Hospital, Seoul 02841, Republic of KoreaDivision of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Korea University Anam Hospital, Seoul 02841, Republic of KoreaDepartment of Laboratory Medicine, Korea University College of Medicine, Seoul 02841, Republic of KoreaDepartment of Laboratory Medicine, Korea University College of Medicine, Seoul 02841, Republic of KoreaDepartment of Laboratory Medicine, Korea University College of Medicine, Seoul 02841, Republic of KoreaDepartment of Laboratory Medicine, Korea University College of Medicine, Seoul 02841, Republic of KoreaWe evaluated the performance of SARS-CoV-2 assays in the vaccinated group using receptor-binding domain antibody assays (RBD Ab assay), neutralizing antibody assay (nAb assay), and interferon-gamma release assay (IGR assay). We also compared the performance of the SARS-CoV-2 assays based on vaccine type in a large population. We collected 1851 samples from vaccinated individuals with vector, mix-and-match (MM), and mRNA vaccines. The performance of the RBD Ab assays was assessed by SARS-CoV-2 IgG II Quant (Abbott Laboratories, Sligo, Ireland), SARS-CoV-2 IgG (Beckman Coulter, CA, USA), and anti-SARS-CoV-2 S (Roche Diagnostics GmbH, Mannheim, Germany). The nAb assay was assessed by cPass SARS-CoV-2 neutralization antibody detection kits (GenScript, NJ, USA). The IGR assay was assessed by QuantiFERON (Qiagen, Venlo, The Netherlands). Median values of the RBD Ab assays and nAb assay sequentially increased after the first and second vaccinations. RBD Ab assays and nAb assay showed very strong correlations. The median values of the RBD Ab, nAb, and IGR were higher in the mRNA vaccine group than in the vector and MM vaccine groups. The agreement and correlation among the RBD Ab assays, nAb assay, and IGR assay were higher in the mRNA vaccine group than in the vector and MM vaccine groups. We compared the performance of the RBD Ab assay, nAb assay, and IGR assay based on the vaccine types using the RBD Ab, nAb, and IGR assays. This study provides a better understanding of the assessment of humoral and cellular immune responses after vaccination.https://www.mdpi.com/2075-4418/13/24/3688antibody binding assayneutralizing assayIGRASARS-CoV-2vaccinevector vaccine |
| spellingShingle | Minjeong Nam Jae Hyun Cha Sang-Wook Kim Sun Bean Kim Ki-Byung Lee You-Seung Chung Seung Gyu Yun Myung-Hyun Nam Chang Kyu Lee Yunjung Cho Performance Evaluation of Three Antibody Binding Assays, a Neutralizing Antibody Assay, and an Interferon-Gamma Release Assay for SARS-CoV-2 According to Vaccine Type in Vaccinated Group Diagnostics antibody binding assay neutralizing assay IGRA SARS-CoV-2 vaccine vector vaccine |
| title | Performance Evaluation of Three Antibody Binding Assays, a Neutralizing Antibody Assay, and an Interferon-Gamma Release Assay for SARS-CoV-2 According to Vaccine Type in Vaccinated Group |
| title_full | Performance Evaluation of Three Antibody Binding Assays, a Neutralizing Antibody Assay, and an Interferon-Gamma Release Assay for SARS-CoV-2 According to Vaccine Type in Vaccinated Group |
| title_fullStr | Performance Evaluation of Three Antibody Binding Assays, a Neutralizing Antibody Assay, and an Interferon-Gamma Release Assay for SARS-CoV-2 According to Vaccine Type in Vaccinated Group |
| title_full_unstemmed | Performance Evaluation of Three Antibody Binding Assays, a Neutralizing Antibody Assay, and an Interferon-Gamma Release Assay for SARS-CoV-2 According to Vaccine Type in Vaccinated Group |
| title_short | Performance Evaluation of Three Antibody Binding Assays, a Neutralizing Antibody Assay, and an Interferon-Gamma Release Assay for SARS-CoV-2 According to Vaccine Type in Vaccinated Group |
| title_sort | performance evaluation of three antibody binding assays a neutralizing antibody assay and an interferon gamma release assay for sars cov 2 according to vaccine type in vaccinated group |
| topic | antibody binding assay neutralizing assay IGRA SARS-CoV-2 vaccine vector vaccine |
| url | https://www.mdpi.com/2075-4418/13/24/3688 |
| work_keys_str_mv | AT minjeongnam performanceevaluationofthreeantibodybindingassaysaneutralizingantibodyassayandaninterferongammareleaseassayforsarscov2accordingtovaccinetypeinvaccinatedgroup AT jaehyuncha performanceevaluationofthreeantibodybindingassaysaneutralizingantibodyassayandaninterferongammareleaseassayforsarscov2accordingtovaccinetypeinvaccinatedgroup AT sangwookkim performanceevaluationofthreeantibodybindingassaysaneutralizingantibodyassayandaninterferongammareleaseassayforsarscov2accordingtovaccinetypeinvaccinatedgroup AT sunbeankim performanceevaluationofthreeantibodybindingassaysaneutralizingantibodyassayandaninterferongammareleaseassayforsarscov2accordingtovaccinetypeinvaccinatedgroup AT kibyunglee performanceevaluationofthreeantibodybindingassaysaneutralizingantibodyassayandaninterferongammareleaseassayforsarscov2accordingtovaccinetypeinvaccinatedgroup AT youseungchung performanceevaluationofthreeantibodybindingassaysaneutralizingantibodyassayandaninterferongammareleaseassayforsarscov2accordingtovaccinetypeinvaccinatedgroup AT seunggyuyun performanceevaluationofthreeantibodybindingassaysaneutralizingantibodyassayandaninterferongammareleaseassayforsarscov2accordingtovaccinetypeinvaccinatedgroup AT myunghyunnam performanceevaluationofthreeantibodybindingassaysaneutralizingantibodyassayandaninterferongammareleaseassayforsarscov2accordingtovaccinetypeinvaccinatedgroup AT changkyulee performanceevaluationofthreeantibodybindingassaysaneutralizingantibodyassayandaninterferongammareleaseassayforsarscov2accordingtovaccinetypeinvaccinatedgroup AT yunjungcho performanceevaluationofthreeantibodybindingassaysaneutralizingantibodyassayandaninterferongammareleaseassayforsarscov2accordingtovaccinetypeinvaccinatedgroup |